drugset / Trial / NCT03048136

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

NCT03048136

Phase 3 Withdrawn Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

Timeline

Start
2018-03-09
Primary completion
2019-09-29
Completion
2019-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody
Subject Nivolumab Monoclonal antibody